— Frost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically examines the industry’s development history, core technology classifications, policy and capital market dynamics, upstream and downstream value chains, bottlenecks in viral vector manufacturing, clinical progress across key indications, reimbursement pathways, and the competitive landscape. It also identifies key challenges and opportunities in vector technologies, large-scale manufacturing, clinical translation, commercial reimbursement, and regulatory frameworks, while exploring the industry’s current landscape and future trends driven by technological breakthroughs, regulatory improvements, capital investment, and commercialization. By connecting industry participants, investment institutions, and regulatory authorities, the report provides forward-looking market insights and strategic guidance for technology planning, product development, industrialization, international collaboration, and the improvement of industry standards. (To read the 2026 Global Gene Therapy Industry Development Blue Book, visit: https://hub.frost.com/global-gene-therapy-industry-development/ )
Gene therapy is an innovative therapeutic approach that treats diseases by modifying, replacing, supplementing, or regulating human genes, targeting genetic abnormalities at the root cause of disease. Unlike conventional drugs that primarily alleviate symptoms or slow disease progression through long-term administration, gene therapy aims to provide one-time or long-lasting therapeutic benefits, offering new possibilities for treating inherited disorders, ophthalmic diseases, cancer, and chronic conditions. With continued advances in gene editing, delivery systems, manufacturing processes, and commercialization capabilities, the global gene therapy industry is transitioning from early-stage technological exploration toward large-scale application.
Key Market Observations from the Blue Book
1. Technological Revolution: Gene Therapy Shifts Disease Treatment from Symptom Management to Addressing Underlying Causes
Gene therapy is built around the principle of addressing the underlying causes of disease. Four core technological approaches have emerged: gene replacement, gene addition, gene expression alteration, and gene editing.
2. Industry Advancement: Scalable Manufacturing and Quality Control Become Critical to Commercialization
As gene therapy pipelines progressively advance into late-stage clinical development and commercial registration, industry competition is shifting from R&D capabilities toward manufacturing capacity and Chemistry, Manufacturing and Controls (CMC) capabilities.
3. Commercialization Prospects: From High-Value Patient Populations to Broader Chronic Disease Markets
The core value of gene therapy lies in its potential to transform disease treatment from continuous drug administration toward one-time intervention with long-term or potentially lifelong benefits.
However, successful commercialization depends not only on technological advancement but also on achieving an appropriate balance between clinical benefits and economic value. In general, diseases associated with a high disease burden, substantial unmet medical needs, and high long-term treatment costs are more likely to offer initial commercialization opportunities.
Global and Chinese Markets Enter an Accelerated Growth Phase
The global gene therapy market is transitioning from early commercialization toward large-scale application. According to the Blue Book, the global gene therapy therapeutics market is projected to grow from USD 0.1 billion in 2021 to USD 32.0 billion by 2035.
Between 2021 and 2025, the market experienced rapid growth from a relatively small base, primarily driven by new product approvals, accelerated clinical translation, and the low-base effect. Growth rates are expected to moderate during 2025 – 2030 and 2030 – 2035, while the overall market continues to expand, reflecting a gradual transition from early-stage market expansion toward more stable growth.
By 2035, the global market is projected to reach USD 32.0 billion, while China’s gene therapy therapeutics market is expected to reach RMB 22.8 billion.
China’s gene therapy therapeutics market is characterized by an early regulatory breakthrough, delayed commercialization growth, and substantial future growth potential. In 2003, Shenzhen SiBiono’s recombinant adenovirus-p53 injection, Gendicine®, received regulatory approval, marking an early milestone in gene therapy product approval and clinical translation in China.
As gene delivery vectors, manufacturing processes, clinical research capabilities, and regulatory review mechanisms continue to mature, alongside growing unmet medical needs in oncology, rare diseases, and inherited disorders, China’s gene therapy market is expected to enter a period of accelerated growth. Future product approvals, expanded clinical applications, improved reimbursement systems, and stronger value chain capabilities will collectively support further market expansion.
Looking ahead, gene therapy commercialization is expected to follow a development pathway characterized by initial breakthroughs in diseases with high treatment burdens, improved clinical translation through well-defined targets and measurable endpoints, and gradual penetration into chronic disease markets.
Ophthalmic diseases, hematologic disorders, and certain rare inherited diseases are expected to establish reimbursement pathways first. Oncology, CNS disorders, cardiovascular diseases, and metabolic conditions may subsequently unlock broader market opportunities as evidence of long-term efficacy, safety, and cost-effectiveness continues to accumulate.
4. Industry Ecosystem: Regulatory, Technological, and Quality Advances Accelerate the Scaling of Gene Therapy
The gene therapy industry is evolving from individual product breakthroughs toward a more mature ecosystem driven by coordinated advances in regulatory policies, technological innovation, and quality management systems.
On the regulatory front, global and Chinese regulatory frameworks continue to evolve, with increasingly clear technical guidelines and expedited approval pathways covering pharmaceutical development, nonclinical research, clinical development, long-term follow-up, and rare disease therapies. These developments are expected to reduce uncertainty in R&D and regulatory registration, facilitating the clinical translation of gene therapy products.
Meanwhile, technological advances in AI-assisted AAV vector design, base editing, RNA editing, and novel delivery systems are improving delivery efficiency, tissue targeting, editing precision, and in vivo safety. These innovations are supporting the expansion of gene therapy from early clinical proof of concept to applications across a broader range of diseases.
About Frost & Sullivan’s Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan’s global think tank resources and the cross-industry business development platform in Greater China, the Life Sciences Practice of Frost & Sullivan has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice of Frost & Sullivan has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating extensive project experience in various sub-sectors of life sciences.
Project types include Knowledge Center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry consulting, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.
Editorial Team
Yiwen Ding
Frost & Sullivan Greater China Life Sciences Consulting Manager
Email: erin.ding@frostchina.com
Contact Info:
Name: Yiwen Ding
Email: Send Email
Organization: Frost & Sullivan
Website: http://www.frostchina.com
Release ID: 89207470
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.